The existence of hepatitis C virus proteins encoded by alternate reading frames overlapping the core-encoding region has been suggested. Several mechanisms of production have been postulated and the function(s) of these proteins in the HCV life cycle remain(s) unknown. We analyzed cases of seroconversion to an alternate reading frame protein in a group of 17 patients infected by the one of two hepatitis C virus genotype 1b strains during an outbreak in a hemodialysis unit. Three patients seroconverted and antibodies were transiently detected in another patient. Three of these patients were infected by one of the two HCV strains, whereas the strain infecting the remaining patient could not be identified. Quasispecies sequence analysis of the core-coding region showed no differences in the core or 1 reading frame sequences that could explain alternate reading frame protein seroconversion in some but + not all of the patients infected by one of the HCV strains, and no such difference was found between the two strains. As differences in the structure of RNA elements could play a role in frameshift events, we conducted a predictive analysis of RNA folding by using RNAfold software. No difference was found between the patients who did and did not seroconvert to alternate reading frame protein.
11
infection is a double-frameshift event. The first ( 1) frameshift would occur at codon 42, located in stem-loop VI of the HCV genome, and + the second ( 1) at codon 144 in the 1 ORF, close to the terminal stem-loops ( ). Rephasing back to translation in the HCV ORF leads to − + 8 production of ARFP-DFC (double frameshift core), whereas interruption of translation after the stop codon leads to the production of ARFP-1b ( ). Internal initiation near codons 85 88 or at codon 26 in the core-encoding sequence has also been suggested to generate 8 -ARFPs in the 1 reading frame (ARFP-86 and ARFP-26, respectively) ( , ).
ARFP/F can be expressed . It is present as a highly basic protein in the cytoplasm of transfected cultured cells, sometimes with in vitro a perinuclear distribution ( ). ARFP/F is unstable, however, and is degraded by the proteasome complex rapidly after its synthesis 11
(half-life about 10 min) ( , ). There is some evidence that ARFPs are produced during HCV infection. Indeed, anti-ARFP antibodies 5 11 have been detected with specific assays in up to 40 of patients with chronic HCV infection, and ARFP-specific T-and B-cell-mediated % responses have been documented ( , , ). However, the frequency and timing of ARFP production during infection, as well as the 5 8 12 -14 role of ARFPs in the HCV lifecycle and pathogenicity, are totally unknown. ARFP does not appear to play a role in viral replication, as subgenomic replicons lacking the full structural region of the genome successfully replicate ( ). The basic nature and in vitro 15 cytoplasmic localization of ARFP are compatible with an interaction with HCV RNA. The possible role of ARFP in the establishment of acute and chronic HCV infection is unknown.
Here we analyzed cases of seroconversion to ARFP in a group of patients infected by the one of two HCV genotype 1b strains during an outbreak in a hemodialysis unit. Our findings prove that ARFP can be produced during acute HCV infection, but not all patients or even all patients infected by a given strain are able to mount a humoral response against it if produced.
MATERIALS AND METHODS

Patients
Six groups of patients were studied ( ). Group I consisted of a cohort of 17 patients (6 males and 11 females, mean age 64 Table 1 years) who developed acute hepatitis C during an outbreak in a Greek hemodialysis unit ( ). The route of transmission was not 16
identified. The patients were infected with one of two distinct HCV genotype 1b strains, nine patients with strain A and seven with strain B (one patient s strain could not be genotyped) ( ). The patients were monitored without treatment during the first 6 months, and blood NA levels were measured in all samples. The seroconversion profiles were characterized by using a semi-quantitative line immunoassay (Inno-LIA HCV IV prototype assay, Innogenetics, Ghent, Belgium) that semi-quantifies antibodies against eight HCV epitopes present in the core, E1, E2, NS3, NS4 and NS5 protein sequences.
Group II consisted of 24 patients with acute viral hepatitis unrelated to HCV: 9 patients had acute hepatitis A, characterized by the presence of anti hepatitis A virus IgM; 15 patients had acute hepatitis B, characterized by a seroconversion to HBs antigen (including 7 patients who presented with symptoms of acute hepatitis and 8 regular blood donors who seroconverted between two donations). Group III consisted of a cohort of 216 patients chronically infected by HCV genotype 1 strains and managed in the Hepatology Department of Henri Mondor hospital, France.
Three control groups of subjects with no markers of HCV infection were used to assess the specificity of our anti-ARFP ELISA.
Group IV consisted of 187 patients managed in medical departments of Henri Mondor hospital who had no serological markers of common viral infections. Group V consisted of 122 patients infected by human immunodeficiency virus (HIV) and Group VI consisted of 93 patients infected by hepatitis B virus (HBV).
Study design
We developed and characterized a sensitive ELISA method for anti-ARFP (43-141) antibody detection. It was used to detect anti-ARFP antibodies in all available serum samples, including serial samples from Group I patients and single samples from Group II and III patients. The nucleotide and deduced amino acid sequences of the HCV core region were determined in all Group I patients. Multiple clones were generated to characterize the quasispecies distribution of the analyzed region. The ARFP sequences were deduced from the core protein-coding sequences and compared between the patients who did and did not seroconvert to ARFP. The core protein-coding sequence contains highly conserved structural RNA elements, including two consecutive stem-loops (V and VI), and two consecutive terminal stem-loops ( ). In order to determine whether the production of anti-ARFP antibodies during acute HCV infection in some 17
patients but not in others was related to structural differences in the core protein-coding sequence of the corresponding HCV strains, we examined sequence variations and predicted their impact on the secondary structure of the core protein-coding region. The prevalence of anti-ARFP antibodies was also measured with our ELISA method in the 24 Group II patients with acute hepatitis A or B in order to assess the specificity of anti-ARFP antibody detection for HCV-related acute hepatitis and in the 216 Group III patients with chronic HCV genotype 1 infection, in order to compare it with the incidence of anti-ARFP seroconversion during acute infection. The specificity of anti-ARFP antibody detection was assessed by testing the patients in Groups IV to VI.
For ELISA detection of anti-ARFP (43-141) antibodies, we used the synthetic peptide G97A, composed of 99 amino acids encoded by codons 43-141 and derived from the 1 ORF of the core protein sequence of HCV genotype 1b isolate HCV-JA ( ). The wells of 
Predictive analysis of conserved secondary structures in core/ARFPcoding sequences
All analyses were performed using the European HCV Database website facilities ( ) ( ), the Clustal W http://euhcvdb.ibcp.fr 19 program ( ) and the Vienna RNA secondary structure server ( ) ( ). We predicted the 18 http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi 20 impact of core protein-coding sequence variations on the RNA secondary structure by using the RNAfold program. Two HCV genotype 1b reference genome sequences from the European HCV database were used (numbered D90208 and M58335). The regions selected to generate stem-loops V and VI and the terminal stem-loops spanned nucleotides 43 to 169 and 438 to 518, respectively, using the A of the AUG initiation codon as position 1. Only nonredundant sequences were analyzed in each patient. In order to eliminate misincorporation errors at the PCR stage, sequences harboring a nucleotide substitution at a position that was fully conserved in all the other sequences were excluded.
RESULTS
Performance of the anti-ARFP (43-141) ELISA
We evaluated the analytical sensitivity of our anti-ARFP (43-141) ELISA by testing several dilutions of an anti-ARFP (43-141) monoclonal antibody produced in mice immunized with the G97A peptide (initial concentration: 2.8 mg/mL; range of dilutions: 1/1000 to 1/128 000). The ELISA started to detect anti-ARFP (43-141) at a concentration of 2.2 10 ng/ L. By comparison, commercial The specificity of our anti-ARFP (43-141) ELISA was 99.4 (95 confidence interval: 99.3 99.5 ) when tested on samples from
Group IV patients, who had no markers of common viral infections (one of the 187 patients fell in the gray zone) ( ). None of the Table 2 4 11 122 HIV-infected patients in Group V had anti-ARFP (43-141) antibodies. In contrast, one (1.1 ) of the 93 HBs antigen-positive patients % in Group VI was positive and seven (7.5 ) fell in the gray zone ( ), suggesting cross-reactivity between the two viruses, as % Table 2 previously reported with another ELISA assay using a similar peptide ( ). 13
The intra-and inter-assay coefficients of variation were determined by testing 15 sera five times each in five different runs. They ranged from 2.5 to 8.1 , suggesting that our ELISA had excellent precision and reproducibility.
% %
Seroconversion to ARFP (43-141) in the 17 Group I patients with acute HCV infection
Seroconversion to ARFP (43-141) was studied in the 17 Group I patients who were infected by one of two distinct HCV genotype 1b strains during an outbreak in a hemodialysis unit ( ). The seroconversion profiles were compared for ARFP (43-141) and for structural 16 and nonstructural HCV proteins in 82 serum samples from the 17 patients, who were sampled roughly every month during the 6-month
follow-up period.
shows the dynamics of anti-ARFP (43-141) antibody titers in the 17 patients. Three patients seroconverted to ARFP (43-141) Figure 1 during the study period (patients 1, 6 and 14), and anti-ARFP (43-141) antibodies were transiently detected in another patient (patient 3).
Patients 1 and 6 were both infected by HCV strain A, whereas the strain infecting patient 14 could not be identified. Patient 3 was also infected by HCV strain A.
shows anti-ARFP (43-141) antibody seroconversion dynamics relative to alanine aminotransferase Figure 2 (ALT) and HCV RNA dynamics in these three patients. Seroconversion occurred respectively 4 and 8 weeks after the ALT peak in patients 1 and 6, and at the time of the ALT peak in patient 14.
shows the profiles of seroconversion to ARFP (43-141) and to eight structural or nonstructural HCV epitopes of the core, E1, Figure 3 E2, NS3, NS4 and NS5 proteins. Fifteen patients seroconverted to the core and nonstructural proteins, while patients 13 and 16 had incomplete seroconversion profiles. Thus, the failure to detect anti-ARFP antibodies in 14 patients was not related to an inability to mount HCV-specific humoral responses.
Analysis of the nucleotide sequence of the core-coding region in the 17 Group I patients with acute HCV infection
In order to assess whether seroconversion to ARFP (43-141) was associated with specific nucleotide sequence motifs in the core-coding region that could explain the occurrence of frameshift events, we characterized the core-coding region quasispecies distribution in the 17 patients with acute HCV infection. Twenty-four clones per sample were generated and their sequence was determined at baseline (earliest available sample) in all the patients except two, for whom PCR amplification of the core protein-coding region was not possible (a patient infected with strain B who did not seroconvert to ARFP, and the patient infected by an unidentified strain who seroconverted to ARFP). As two patients infected with HCV strain A infection seroconverted to ARFP (43-141) during follow-up, quasispecies sequence analysis was repeated on the latest available sample in all the patients infected by HCV strain A (except for one patient who did not seroconvert to ARFP and in whom PCR amplification of the target region was not possible). A total of 504 full-length core protein-coding region sequences were analyzed.
The G97A peptide used to detect anti-ARFP (43-141) antibodies in our ELISA showed a high percentage of homology with the putative ARFP sequences deduced from the core protein-coding sequence in the patients, ranging from 88.5 to 91.0 (99 amino acids). (ii) The regions surrounding codons 42 and 144, which have been reported to harbor a double frameshift event ( ), were highly conserved 8
and did not differ between the patients who seronconverted to ARFP (43-141) and those who did not ( ). (iii) Codon 26 Figures 4B and 4C in the 1 reading frame, which has been described as a potential site for internal initiation of translation of ARFP proteins ( ), had GTG Overall, no differences in the core or 1 reading frame sequences were found that could explain ARFP (43-141) seroconversion in two + of the patients infected by HCV strain A, and no such difference was found between strains A and B. The studied regions were highly conserved and no sequence known to be potentially associated with a 1 frameshift was found in any variant from any patient.
+
Predictive analysis of conserved secondary structures in the core protein coding sequence
As differences in the structure of RNA elements could play a role in frameshift events and may not be readily identified by sequence analysis of the core protein coding region, we conducted a predictive analysis of RNA folding by using RNAfold software. The regions spanning nucleotides 43 169 and 438 518 were used to predict the structures of stem-loops V and VI and of the terminal stem-loops, --respectively. Only non-redundant sequences from each patient were included in the analysis, and sequences harboring one nucleotide substitution at a fully conserved position among all the other sequences were removed in order to exclude potential PCR errors. A final set of 76 sequences spanning stem-loops V and VI (53 and 23 sequences from patients infected by strains A and B, respectively) and 69 sequences spanning the terminal loops (51 and 18 sequences from patients infected by strains A and B, respectively) was analyzed in comparison with two reference HCV genotype 1b strains.
We observed strong conservation of predicted structural elements in the core coding sequence, with only a minority of sequences generating different RNA folding predictions (5 for stem-loops V and VI, and 2.2 for the terminal stem-loops).
shows the % % Figure 5 predicted secondary structures of stem-loops V and VI. Four folding predictions were generated, with the strain A consensus sequence, patient 1 s major quasispecies sequence, the strain B consensus sequence, and the reference sequence M58335, respectively. Stem-loop V ' successively includes a long 10-basepair stem followed by a conserved bulge, a 4-base-pair stem and the 5-nucleotide loop. This structure was conserved in the HCV strain A consensus sequence, whereas an additional bulge at the beginning of the long stem was predicted in the HCV strain B consensus sequence ( ). Stem-loop VI successively includes a 7-base-pair stem followed by a conserved bulge, a Figure 5 7-base-pair stem, two conserved excluded adenines, a variable 10-to 13-basepair stem, another conserved bulge, a 4-base-pair stem, and the final loop (6 nucleotides) (
). Figure 5 The strain A consensus sequence structure differed from that of the reference strains and strain B by a variation in the first bulge of stem-loop VI ( ). However, this difference was not found in the major quasispecies variant from patient 1, as a C to U substitution Figure 5 at position 93 restored the reference secondary structure ( ). Thus, patients 1 and 6, who both seroconverted to ARFP (43-141), Figure 5 had different predicted stem-loops VI, whereas stem-loop VI was identical in patient 6 and in the patients infected by strain A who did not seroconvert to ARFP (43-141). Only one substitution distinguished patients 1 and 6 from the other patients infected by strain A, namely an A to G substitution at position 59, which altered the conserved bulge in stem-loop V and added one base pair to the stem ( ). Other Figure 5 point substitutions were found in patient 1 and patient 6 ( ). Figure 5 The terminal stem-loops were also highly conserved among the different patients, as a result of strong conservatory constraints on the sequence of the core protein. No difference was found between the patients infected by strain A who did and did not seroconvert to ARFP (43-141). Rare substitutions sometimes affected the number of predicted stem-loops (data not shown), but they bore no relationship to ARFP (43-141) seroconversion.
Prevalence of anti-ARFP (43-141) antibodies in patients with acute hepatitis A or B (Group II)
None of the 9 patients with acute hepatitis A had detectable anti-ARFP (43-141) antibodies. One blood donor with an HBs antigen seroconversion (out of 15 patients with acute hepatitis B) was found to be positive in our anti-ARFP (43-141) ELISA but was negative on repeat testing, confirming possible cross-reactivity between the two viruses.
Prevalence of anti-ARFP (43-141) antibodies in patients with chronic HCV genotype 1 infection (Group III)
Twenty-six (12.3 ) of the 216 patients with chronic HCV genotype 1 infection (Group II) had detectable anti-ARFP (43-141) % antibodies in our ELISA.
DISCUSSION
Our observation of seroconversion to ARFP (43-141) in three patients and transient detection in one patient with dated acute HCV infection proves that ARFPs are produced during HCV infection, that they are expressed early in the acute phase of infection, and that their production can trigger a specific humoral response. In two of the three patients who seroconverted, anti-ARFP (43-141) antibodies emerged several weeks after antibodies against the main ORF proteins, both structural and nonstructural. This may point to late ARFP production during infection, or may simply reflect the slightly lower sensitivity of our anti-ARFP (43-141) antibody ELISA relative to commercial anti-HCV assays. In the third patient anti-ARFP (43-141) antibodies were detected one week before anti-core antibodies, and no other antibodies emerged during the short follow-up period of a few months. Our anti-ARFP (43-141) antibody assay was highly specific, virtually ruling out false-positive results. Importantly, anti-ARFP (43-141) antibodies were not found in acute viral hepatitis of other causes.
strains. This situation is ideal for studying the respective roles of viral and host factors. Indeed, two patients infected by strain A, but none of the patients infected by strain B, developed anti-ARFP (43-141) antibodies, suggesting that some HCV strains but not others express ARFP. However, the number of patients was relatively small, and a third patient with an untypeable strain also developed anti-ARFP (43-141) antibodies. More interesting is the fact that only two of the nine patients infected by the same HCV strain A experienced anti-ARFP (43-141) antibody seroconversion. In the patients who did not have detectable anti-ARFP (43-141) antibody seroconversion, it was not possible to know if ARFP was not produced, or was produced but the patients failed to mount a detectable anti-ARFP (43-141) antibody response, or the antibody response was not detectable with our assay. In this respect, it is of interest that 10 out of our 17 patients had no evidence of anti-NS5B antibodies, as shown in , whereas it is obvious that they all produced the NS5B RNA-dependent Figure 3 RNA polymerase, the viral enzyme needed for replication. We were not able to study the possible role of host factors in this variability, or the underlying mechanisms. It also remains to be determined whether or not anti-ARFP (43-141) antibody seroconversion can occur later in patients who develop chronic HCV infection. This could not be studied, as our patients were treated when the acute infection did not resolve spontaneously after 6 months of follow-up.
The prevalence of anti-ARFP (43-141) antibodies was 12.6 in our patients with chronic HCV genotype 1 infection, a rate lower than % in another study ( ). The difference could be due to a cohort effect (only patients infected with HCV genotype 1a were tested in the other 13 study) or to the use of a longer antigen (160 amino acids instead of 99 in our assay) and/or a less stringent cut-off in the latter study ( ). 13
Contrary to the acutely infected patients in our study, our chronically infected patients were unrelated and were infected by different HCV genotype 1 strains. Two factors may have played a role in the production of anti-ARFP (43-141) antibodies in these patients, namely the intrinsic capacity of the infecting viral strain to produce ARFP, and host factors regulating ARFP production and/or the humoral response to ARFP.
In an attempt to identify viral characteristics potentially explaining why only some patients seroconverted to ARFP (43-141), we analyzed the sequence of the core protein-coding region quasispecies. The aim was to detect sequences known to be associated with ARFP production in major or minor quasispecies populations. We focused on sites previously implicated in ARFP production, such as the adenine cluster at codons 8 11, the frameshift codons 42 and 144, and the internal initiation codons 26 and 85 88 ( , , ). No
sequences potentially involved in ARFP production were found and no difference was seen between strains A and B, or between the HCV strains infecting patients who seroconverted and those who did not. Likewise, predictive structural analysis of the core protein-coding sequence showed no differences between the patients who seroconverted and those who did not. These results suggest that ARFPs are probably encoded by minority variants that cannot be detected by clonal sequence analysis of serum samples. Alternatively, the expression of ARFP-encoding variants may be transient, leading to brief ARFP production that is sufficient to trigger a humoral response in some patients but not in others. The lack of seroconversion could be due to a lack of ARFP production, excessively brief ARFP expression, an expression level too low to elicit specific antibodies, or an inability of our assay to detect low levels of these antibodies. The observed conservation of predicted ARFP sequences in our patients rules out a failure of our assay to detect antibodies directed at different antigenic sequences.
In conclusion, our observation of anti-ARFP (43-141) antibody production in some hemodialysis patients acutely infected with one of two HCV genotype 1b strains during a nosocomial outbreak is the strongest argument to date that ARFPs are produced during HCV infection. Our findings also indicate that ARFP production occurs early during infection. ARFP could be generated by minority quasispecies variants or variants that occur transiently at the beginning of infection. Our findings throw no light on the possible function of ARFP. The patients who did and did not seroconvert did not differ by their clinical outcomes, severity of infection, or seroconversion profiles. The role of ARFP in the replicative cycle and pathogenicity of HCV remains to be unraveled.
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Figure 2
Respective kinetics of HCV RNA (black circles), alanine aminotransferase (ALT, white squares) and anti-ARFP (43-141) antibodies (gray arrow) in the three patients who seroconverted to ARFP (43-141).
Figure 3
Seroconversion profiles in the 17 patients infected with one of two genotype 1b strains during an HCV outbreak in a hemodialysis unit. The blue bars indicate the detection of anti-ARFP (43-141) antibodies in our enzyme immunoassay; the other bars indicate the detection of antibodies directed at antigens encoded by the main HCV ORF in a prototype line immunoassay (yellow: low titer; orange: medium titer; brown: high titer).
Figure 4
Summary of quasispecies sequence analysis in the 17 patients infected by one of two genotype 1b strains during an HCV outbreak in a hemodialysis unit. Each different variant sequence is reported, with its frequency among the 504 analyzed sequences on the right. Five genomic regions that might be involved in frameshift events were studied (see 
